Benign neoplasms

Familial Adenomatous Polyposis Epidemiology Forecast Research Report 2021-2030 - ResearchAndMarkets.com

Retrieved on: 
Monday, July 26, 2021
Health, General Health, Cancer, Neoplasms, Clinical medicine, Gastrointestinal cancer, Hereditary cancers, Benign neoplasms, Familial adenomatous polyposis, Polyp, Oncology, Adenoma, FAP, Attenuated familial adenomatous polyposis

The "Familial Adenomatous Polyposis - Epidemiology forecast - 2030" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Familial Adenomatous Polyposis - Epidemiology forecast - 2030" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • This 'Familial Adenomatous Polyposis (FAP)-Epidemiology Forecast - 2030' report delivers an in-depth understanding of the Familial Adenomatous Polyposis (FAP), historical and forecasted epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
  • The Familial Adenomatous Polyposis (FAP) epidemiology division provides insights about the historical and current patient pool along with the forecasted trend for every seven major countries.
  • The disease epidemiology covered in the report provides historical as well as forecasted Familial Adenomatous Polyposis (FAP) epidemiology segmented as the Prevalent Cases of Familial Adenomatous Polyposis, Diagnosed cases of Familial Adenomatous Polyposis, Etiology-specific Prevalence of Familial Adenomatous Polyposis, Type-specific Prevalence of Familial Adenomatous Polyposis.

Global Uterine Fibroids Epidemiology and Patient Flow Research Report 2021: Prevalence, Diagnosed, and Drug-treated Patients to 2035 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, July 14, 2021
Health, Pharmaceutical, Benign neoplasms, Gynaecological neoplasia, Uterine fibroid, Clinical medicine, Medicine, Health, Uterine artery embolization

The "Global Uterine Fibroids Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Uterine Fibroids Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com's offering.
  • Global Uterine Fibroids Epidemiology and Patient Flow Analysis - 2021, provides Uterine Fibroids epidemiology, demographics, and patient flow.
  • The research provides population data to characterize Uterine Fibroids patients, history of the disease at the population level (Uterine Fibroids prevalence, Uterine Fibroids incidence) and at the clinical level (from diagnosis to treated patients).
  • Demographics: Uterine Fibroids patients by age group, gender
    The data from this research will help executives:
    Establish basis for Uterine Fibroids market sizing, assessing market potential, and developing drug forecast models
    Identify Uterine Fibroids patients segments through age groups, gender, and disease sub-types
    Evaluate Uterine Fibroids market opportunities, identify target patient population
    View source version on businesswire.com: https://www.businesswire.com/news/home/20210714005471/en/

The Fibroid Foundation Announces the 2021 Fibroid Awareness Month Event Schedule

Retrieved on: 
Tuesday, June 29, 2021
Anatomy, Benign neoplasms, Gynaecological neoplasia, Fibroid, Uterine fibroid, Uterus, Health, Branches of biology

WASHINGTON, June 29, 2021 /PRNewswire/ -- The Fibroid Foundation announces the Fibroid Awareness Month event schedule for July 2021.

Key Points: 
  • WASHINGTON, June 29, 2021 /PRNewswire/ -- The Fibroid Foundation announces the Fibroid Awareness Month event schedule for July 2021.
  • During Fibroid Awareness Month, the programming will focus on helping the fibroid community to Live Their Best Lifeby featuring virtual segments onexercise, nutrition, legislation, research and peer-to-peer support provided by The Fibroid Foundation's chapters.
  • 2007 , introduced in The House of Representatives by Representative Yvette D. Clarke (NY-9) in March,will provide long-overdue fibroid research funding.
  • The Stephanie Tubbs Jones Uterine Fibroid Research and Education Act of 2021 will provide $150 millionto the National Institutes of Health.

BioAxone BioSciences Announces License of Cerebral Cavernous Malformations Drug Candidate BA-1049 and Portfolio of Rho Kinase Inhibitors to Neurelis

Retrieved on: 
Monday, June 21, 2021
General Health, Pharmaceutical, Health, Medicine, Clinical medicine, Health, Benign neoplasms, Epilepsy, Cavernous hemangioma, Neurological disorder, Neurosurgery, Stroke, Epilepsy in animals, BioAxone BioSciences, Inc., Neurelis, Inc., the Angioma Alliance, BIOAXONE BIOSCIENCES, INC., NEURELIS, INC., THE ANGIOMA ALLIANCE

CCMs may cause stroke, seizures, paralysis, or other neurological symptoms dependent on their location in the brain.

Key Points: 
  • CCMs may cause stroke, seizures, paralysis, or other neurological symptoms dependent on their location in the brain.
  • The standard of care is watchful waiting until neurosurgical removal of a leaky lesion is deemed un-avoidable.
  • Neurelis was founded to license, develop, and commercialize product candidates for the broader central nervous system, including epilepsy and psychiatry.
  • They facilitate and participate in cavernous angioma research through collaboration with researchers, research institutions and the biotechnology industry.

Myovant Sciences and Pfizer Receive FDA Approval for MYFEMBREE®, the First Once-Daily Treatment for Heavy Menstrual Bleeding Associated With Uterine Fibroids

Retrieved on: 
Wednesday, May 26, 2021
Drugs, Benign neoplasms, Neoplasms, Clinical medicine, Uterine fibroid, Leiomyoma, Heavy menstrual bleeding, Pfizer, Medroxyprogesterone acetate

The approval of MYFEMBREE represents the second FDA product approval for Myovant in less than one year.

Key Points: 
  • The approval of MYFEMBREE represents the second FDA product approval for Myovant in less than one year.
  • MYFEMBREEs approval is a testament to the shared commitment between Myovant and Pfizer to support women living with uterine fibroids, said Nick Lagunowich, Global President, Internal Medicine at Pfizer.
  • Myovant and Pfizer are committed to supporting women in the U.S. who are prescribed MYFEMBREE throughout their treatment journeys.
  • MYFEMBREE is indicated for the management of heavy menstrual bleeding associated with uterine leiomyomas (fibroids) in premenopausal women.

The Fibroid Foundation is Proud to Support the 'Stephanie Tubbs Jones Uterine Fibroid Research and Education Act of 2021'

Retrieved on: 
Friday, March 19, 2021
Benign neoplasms, Gynaecological neoplasia, Fibroid, Uterine fibroid, Tubbs

WASHINGTON, March 19, 2021 /PRNewswire/ -- The Fibroid Foundation is proud to endorse the 'Stephanie Tubbs Jones Uterine Fibroid Research and Education Act of 2021'.This important legislation was introduced on March 18, 2021, by Representative Yvette D. Clarke (NY-9).

Key Points: 
  • WASHINGTON, March 19, 2021 /PRNewswire/ -- The Fibroid Foundation is proud to endorse the 'Stephanie Tubbs Jones Uterine Fibroid Research and Education Act of 2021'.This important legislation was introduced on March 18, 2021, by Representative Yvette D. Clarke (NY-9).
  • Sateria Venable, Founder & CEO of The Fibroid Foundation, responded to yesterday's introduction of the Fibroid Bill by saying, "Consistent fibroid research funding will transform the quality of life for millions of women in the United States."
  • Legislative benefits of the Uterine Fibroid Act include:
    The Fibroid Foundation, with members in most U.S. states, and 48 countries, develops annual programming centered on education, advocacy and access to treatment.
  • The Fibroid Foundation is proud to support the 'Stephanie Tubbs Jones Uterine Fibroid Research and Education Act of 2021'.

Gynesonics Announces That Detroit Medical Center Huron Valley-Sinai Hospital has Introduced Sonata, A New Innovative, Incision-Free Treatment for Symptomatic Uterine Fibroids

Retrieved on: 
Thursday, January 21, 2021
Health, Medical devices, Consumer, Women, Surgery, Other Health, General Health, Detroit Medical Center, Tenet Healthcare, Neoplasms, Benign neoplasms, Medicine, Gynaecological neoplasia, Uterine fibroid, Clinical medicine, Sinai-Grace Hospital, Huron Valley-Sinai Hospital, Transcervical, Uterine artery embolization, Sonata System, Gynesonics

Gynesonics, a womens healthcare company focused on the development of minimally invasive solutions for symptomatic uterine fibroids, announced today that Detroit Medical Center (DMC) Huron Valley-Sinai Hospital is the first hospital in Michigan to introduce the Sonata Procedure.

Key Points: 
  • Gynesonics, a womens healthcare company focused on the development of minimally invasive solutions for symptomatic uterine fibroids, announced today that Detroit Medical Center (DMC) Huron Valley-Sinai Hospital is the first hospital in Michigan to introduce the Sonata Procedure.
  • Symptoms may worsen over time if fibroids are left untreated, which leads to more than two million women in the U.S. undergoing treatment for uterine fibroids each year.
  • I was very impressed by the results of the clinical studies, and the positive impact Sonata had on womens lives.
  • Gynesonics has developed the Sonata System for diagnostic intrauterine imaging and transcervical treatment of symptomatic uterine fibroids.

FDA Approves First Intratumoral Injection to Treat Non-Metastatic Mast Cell Tumors in Dogs

Retrieved on: 
Monday, November 16, 2020
Animal diseases, Mastocytoma, Cancer, Medicine, Metástasis, Benign neoplasms, Cancer in dogs, Mediastinal germ cell tumor, Germ cell tumor

"This is the first approval for an intratumoral injection to treat non-metastatic mast cell tumors in dogs," said Steven M. Solomon, D.V.M., M.P.H., director of the FDA's Center for Veterinary Medicine.

Key Points: 
  • "This is the first approval for an intratumoral injection to treat non-metastatic mast cell tumors in dogs," said Steven M. Solomon, D.V.M., M.P.H., director of the FDA's Center for Veterinary Medicine.
  • "This approval provides an additional treatment option to help treat local mast cell tumors on or under the skinin dogs."
  • Full surgical removal of mast cell tumors can be difficult when tumors are located in certain areas, such as the leg.
  • When mast cell tumors are not fully removed, the remaining malignant cells can start to grow and spread rapidly.

Sonata, a New Innovative, Incision-Free Procedure to Treat Symptomatic Uterine Fibroids, Expands in New York Area

Retrieved on: 
Tuesday, October 27, 2020
Health, Medical devices, Consumer, Hospitals, Women, Surgery, Radiology, Benign neoplasms, Anatomy, Gynaecology, Gynaecological neoplasia, Uterine fibroid, Clinical medicine, Uterus, Uterine myomectomy, Heavy menstrual bleeding, Sonata System, Gynesonics

Symptoms may worsen over time if fibroids are left untreated, which leads to more than two million women in the U.S. undergoing treatment for uterine fibroids each year.

Key Points: 
  • Symptoms may worsen over time if fibroids are left untreated, which leads to more than two million women in the U.S. undergoing treatment for uterine fibroids each year.
  • NewYork-Presbyterian Lawrence Hospital in Bronxville, N.Y., where the procedure is performed, began using the Sonata System in July.
  • We can now offer a new advanced gynecologic treatment option for some women with symptomatic uterine fibroids that is incision-free, fast and can be particularly beneficial during childbearing years.
  • Gynesonics has developed the Sonata System for diagnostic intrauterine imaging and transcervical treatment of symptomatic uterine fibroids.

Familial Adenomatous Polyposis Pipeline Review, H2 2020 - Therapeutic Analysis of 12 Companies & 5 Drug Profiles - ResearchAndMarkets.com

Retrieved on: 
Thursday, October 1, 2020
Pharmaceutical, Genetics, Health, Oncology, Hereditary cancers, Clinical medicine, Neoplasms, Gastrointestinal cancer, Health, Benign neoplasms, Familial adenomatous polyposis, Polyp, Genodermatoses, Hereditary intestinal polyposis

Familial Adenomatous Polyposis - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Familial Adenomatous Polyposis (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

Key Points: 
  • Familial Adenomatous Polyposis - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Familial Adenomatous Polyposis (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
  • The Familial Adenomatous Polyposis (Genetic Disorders) pipeline guide also reviews the key players involved in therapeutic development for Familial Adenomatous Polyposis and features dormant and discontinued projects.
  • The pipeline guide reviews pipeline therapeutics for Familial Adenomatous Polyposis (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Formulate corrective measures for pipeline projects by understanding Familial Adenomatous Polyposis (Genetic Disorders) pipeline depth and focus of Indication therapeutics.